+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuroprotection Market - Global Forecast 2026-2032- Product Image
Neuroprotection Market - Global Forecast 2026-2032- Product Image
New

Neuroprotection Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4857892
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuroprotection market is rapidly evolving as industry leaders across pharmaceuticals, biotechnology, and healthcare coordinate to address the pressing need for innovative neurological therapies. Strategic shifts in research, development, and care delivery are shaping a competitive and dynamic sector for organizations seeking growth and resilience.

Market Snapshot: Neuroprotection Market Growth and Dynamics

The global neuroprotection market expanded from USD 336.31 billion in 2025 to USD 359.74 billion the subsequent year, progressing at a robust 7.93% CAGR and estimated to reach USD 573.80 billion by 2032. This rise is fueled by an integrated approach combining pharmaceutical development, clinical research, and healthcare service enhancement to deliver novel solutions that prevent or slow neuronal loss. Innovations in drug delivery mechanisms and digital health tools are strengthening the industry’s capacity to address complex neurological disorders. Stakeholders are intensifying efforts around both chronic neurodegenerative and acute neurological conditions, motivating strategic engagement among providers, payers, and advocacy groups throughout the sector.

Scope & Segmentation

  • Product Types: Biologics—including monoclonal antibodies and neurotrophic factors—along with small molecule drugs, gene therapies, nutraceuticals with herbal extracts and micronutrients, as well as stem cell therapies, form a broad portfolio supporting tailored neuroprotection strategies.
  • Mechanisms of Action: Drug development targets diverse neurobiological pathways via anti-inflammatory agents, antioxidants, calcium channel blockers, glutamate inhibitors, neurotrophic factors, and NMDA antagonists. This range fosters personalized approaches that can respond to shifting clinical needs.
  • End Users: Hospitals, clinics, home healthcare providers, and research institutes each demand specific operational and logistical solutions for delivering interventions across a spectrum of patient scenarios.
  • Indications: Solutions address both chronic and acute neurodegenerative disorders, including stage-specific Alzheimer’s Disease, variants of Multiple Sclerosis and Parkinson’s Disease, plus multiple subtypes of stroke. This diversity highlights the requirement for adaptable treatment pathways.
  • Distribution Channels: Hospital, online, and retail pharmacies provide access to neuroprotective therapies, each with logistical, reimbursement, and accessibility considerations that influence commercial planning and supply chain execution.
  • Regions Covered: Strategic variations in regulatory frameworks, reimbursement models, research investment, and patient access are seen across Americas, EMEA, and Asia-Pacific, informing regional market positioning and growth initiatives.
  • Technological Advancements: Adoption of omics-based patient classification, advanced drug delivery systems, adaptive clinical trial methods, and digital health integration are central to accelerating innovation and translating breakthroughs to real-world impact.

Key Takeaways for Senior Decision-Makers

  • Investing in biomarker development and optimizing manufacturing supports the transition from research to clinical practice, paving the way for earlier patient access to emerging neurotherapies.
  • Strategic differentiation relies on aligning product modality, mechanism of action, and patient context, guiding R&D focus and determining commercial potential.
  • Collaborating with academic partners, CROs, and technology firms can broaden resource access and expedite regulatory milestones in complex development programs.
  • Leveraging real-world evidence and focusing on patient-centered trial measures are essential for demonstrating value to both payers and regulatory agencies, supporting favorable reimbursement and access outcomes.
  • Tailoring operations to regional demands ensures regulatory compliance, optimal patient engagement, and alignment with local ecosystem maturity, boosting operational resilience.
  • Building resilient supply chains through diverse sourcing and proactive planning can reduce exposure to trade or geopolitical risks and secure uninterrupted therapy availability.

Tariff Impact on Supply Chains and Innovation Incentives

Recent U.S. tariff actions have prompted neuroprotection companies to adjust procurement and supplier strategies. Increased import duties on core pharmaceutical components and evolving customs requirements have led many organizations to prioritize supply chain resilience. Strategies such as onshoring, nearshoring, or establishing adaptable partnership networks are being implemented to safeguard product flow and sustain research momentum. These responses are also reshaping clinical trial logistics and highlight the importance of agile supplier management through all stages of development and commercialization.

Methodology & Data Sources

Market analysis draws from systematic secondary research, including peer-reviewed articles, trial registries, regulatory filings, and public corporate disclosures. This is complemented by primary interviews with clinicians, regulatory experts, supply chain leaders, payers, and industry strategists. All insights are synthesized through cross-segment analysis and peer validation to ensure reliability.

Why This Report Matters

  • Offers actionable guidance for aligning innovation and operational strategy within evolving regulatory and market landscapes.
  • Includes in-depth segmentation and regional insights, enabling more informed portfolio development, investment allocation, and patient-access planning.
  • Equips senior leaders to anticipate and address external pressures—from digital integration to tariffs—supporting streamlined decision-making and resource prioritization.

Conclusion

Effective navigation of the neuroprotection landscape relies on strategically coordinating scientific and operational activities. By integrating breakthroughs, adapting to regional dynamics, and fostering resilient supply models, organizations can sustain progress in neurological care under changing industry conditions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neuroprotection Market, by Product Type
8.1. Biologics
8.1.1. Monoclonal Antibody Biologics
8.1.2. Neurotrophic Factor Biologics
8.2. Drugs
8.2.1. Peptide Drugs
8.2.2. Small Molecule Drugs
8.3. Gene Therapy
8.4. Nutraceuticals
8.4.1. Herbal Extract Nutraceuticals
8.4.2. Mineral Nutraceuticals
8.4.3. Vitamin Nutraceuticals
8.5. Stem Cell Therapy
9. Neuroprotection Market, by Mechanism Of Action
9.1. Anti Inflammatory Agents
9.1.1. Cytokine Inhibitor Anti Inflammatory Agents
9.1.2. NSAID Anti Inflammatory Agents
9.1.3. Steroid Anti Inflammatory Agents
9.2. Antioxidants
9.2.1. Flavonoid Antioxidants
9.2.2. Vitamin C Antioxidants
9.2.3. Vitamin E Antioxidants
9.3. Calcium Channel Blockers
9.3.1. Flunarizine Calcium Channel Blockers
9.3.2. Nimodipine Calcium Channel Blockers
9.4. Glutamate Inhibitors
9.5. Neurotrophic Factors
9.6. NMDA Antagonists
9.6.1. Ketamine NMDA Antagonists
9.6.2. Memantine NMDA Antagonists
10. Neuroprotection Market, by Indication
10.1. Alzheimer's Disease
10.1.1. Early Stage Alzheimer's Disease
10.1.2. Moderate Stage Alzheimer's Disease
10.1.3. Severe Stage Alzheimer's Disease
10.2. Multiple Sclerosis
10.2.1. Relapsing Remitting Multiple Sclerosis
10.2.2. Secondary Progressive Multiple Sclerosis
10.3. Parkinson's Disease
10.3.1. Postural Instability Parkinson's Disease
10.3.2. Tremor Dominant Parkinson's Disease
10.4. Spinal Cord Injury
10.5. Stroke
10.5.1. Hemorrhagic Stroke
10.5.2. Ischemic Stroke
10.6. Traumatic Brain Injury
11. Neuroprotection Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Neuroprotection Market, by End User
12.1. Clinics
12.2. Home Healthcare
12.3. Hospitals
12.4. Research Institutes
13. Neuroprotection Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Neuroprotection Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Neuroprotection Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Neuroprotection Market
17. China Neuroprotection Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AC Immune SA
18.6. Alector, Inc.
18.7. Amgen Inc.
18.8. AstraZeneca PLC
18.9. Axsome Therapeutics, Inc.
18.10. BioArctic AB
18.11. Biogen Inc.
18.12. Cassava Sciences, Inc.
18.13. Denali Therapeutics, Inc.
18.14. Eisai Co., Ltd.
18.15. Eli Lilly and Company
18.16. F. Hoffmann-La Roche Ltd
18.17. Ionis Pharmaceuticals, Inc.
18.18. Neurocrine Biosciences, Inc.
18.19. Novartis AG
18.20. Pfizer Inc.
18.21. Takeda Pharmaceutical Company Limited
18.22. UCB S.A.
18.23. Vivoryon Therapeutics N.V.
18.24. Voyager Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. AMERICAS NEUROPROTECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 170. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 171. AMERICAS NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 172. AMERICAS NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 173. AMERICAS NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 174. AMERICAS NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 175. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 176. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 177. AMERICAS NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 178. AMERICAS NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 179. AMERICAS NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 180. AMERICAS NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 181. AMERICAS NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 182. AMERICAS NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 183. AMERICAS NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 184. AMERICAS NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 189. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 190. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 191. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 192. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 193. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 194. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 195. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 196. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 197. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 198. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 199. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 200. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 201. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 205. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 206. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 207. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 208. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 209. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 210. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 211. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 212. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 213. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 214. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 215. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 216. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 217. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 218. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. EUROPE NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. EUROPE NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 239. EUROPE NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 240. EUROPE NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 241. EUROPE NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 242. EUROPE NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 243. EUROPE NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 244. EUROPE NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 245. EUROPE NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 246. EUROPE NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 247. EUROPE NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 248. EUROPE NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 249. EUROPE NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 250. EUROPE NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 251. EUROPE NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 252. EUROPE NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 253. EUROPE NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 255. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 256. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 257. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 258. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 259. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 260. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 261. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 262. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 263. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 264. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 265. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 266. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 267. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 268. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 269. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 270. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 271. AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 272. AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 273. AFRICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 274. AFRICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 275. AFRICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 276. AFRICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 277. AFRICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 278. AFRICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 279. AFRICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 280. AFRICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 281. AFRICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 282. AFRICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 283. AFRICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 284. AFRICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 285. AFRICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 286. AFRICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 287. AFRICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 288. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 289. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 290. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 291. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 292. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 293. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 294. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 295. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 296. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 297. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 298. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 299. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 300. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 301. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 302. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 303. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 305. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 306. ASEAN NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 307. ASEAN NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 308. ASEAN NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 309. ASEAN NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
TABLE 310. ASEAN NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
TABLE 311. ASEAN NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 312. ASEAN NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 313. ASEAN NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
TABLE 314. ASEAN NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
TABLE 315. ASEAN NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
TABLE 316. ASEAN NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 317. ASEAN NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
TABLE 318. ASEAN NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
TABLE 319. ASEAN NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
TABLE 320. ASEAN NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
TABLE 321. ASEAN NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 322. ASEAN NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 323. GCC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 324. GCC NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MI

Companies Mentioned

The key companies profiled in this Neuroprotection market report include:
  • AC Immune SA
  • Alector, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Axsome Therapeutics, Inc.
  • BioArctic AB
  • Biogen Inc.
  • Cassava Sciences, Inc.
  • Denali Therapeutics, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals, Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Vivoryon Therapeutics N.V.
  • Voyager Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 359.74 Billion
Forecasted Market Value ( USD ) by 2032 $ 573.8 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Neuroprotection Therapeutics - Global Strategic Business Report - Product Image

Neuroprotection Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172

  • Book
  • Global
Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2 - Product Image

Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2

  • Book
  • Global
Indopathy for Neuroprotection: Recent Advances - Product Image

Indopathy for Neuroprotection: Recent Advances

  • Book
Neurology Devices Market - Global Forecast 2026-2032 - Product Image

Neurology Devices Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From

About the Neuroprotection Market

The Neuroprotection market within the context of Neurology Devices is focused on the development of products that protect the brain from damage caused by stroke, traumatic brain injury, and other neurological disorders. These products are designed to reduce the risk of long-term neurological damage and improve patient outcomes. Neuroprotection products include drugs, medical devices, and other therapies that can be used to reduce the risk of neurological damage. These products are used to reduce the risk of stroke, traumatic brain injury, and other neurological disorders. The Neuroprotection market is a rapidly growing segment of the Neurology Devices market, with a focus on improving patient outcomes and reducing the risk of long-term neurological damage. Companies in this market include Medtronic, Abbott, Boston Scientific, Stryker, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.